#ICYMI: Positive results from Part 1 of our Phase 2 ELIMINATE trial are published in The Lancet Infectious Diseases! LBP-EC01, our CRISPR-Cas3 engineered #bacteriophage, targets #UTIs caused by #AMR & #MDR E. coli. locus-bio.com/locus-bioscien…

Exciting news! Locus has been awarded $4.1M from @CARB_X to support the development of an engineered #bacteriophage therapy targeting infections caused by antimicrobial-resistant (#AMR) and multi-drug-resistant (#MDR) K. pneumoniae.

Positive results from Part 1 of our Phase 2 ELIMINATE trial evaluating genetically engineered bacteriophage therapy, LBP-EC01, to treat #UTIs were published in @TheLancet Infectious Diseases. Additionally, dosing has begun in Part 2 portion of this study. globenewswire.com/news-relea…

Excited for #BIO2024? Want to learn about our work to develop #precisionmedicines including bacteriophage-based therapies to combat antibiotic resistance and treat #immunology diseases including inflammatory bowel disease (#IBD)? Let’s connect. auth.inova-application.com/a…

Celebrating 9 Years of Innovation and Impact! Pioneering #precisionmedicine with engineered bacteriophage therapy, combating antibiotic-resistant infections, and #immunology diseases like #IBD. Grateful for support as we continue revolutionizing treatment! #LocusTurns9

We’re excited to attend #DDW2024! As Locus develops #precisionmedicines to treat #immunology diseases including #IBD, we look forward to meeting with researchers, clinicians, and industry leaders to discuss how together we can push the boundaries of medicine.

Happy #DNADay24! We honor the discovery of DNA's double helix structure and the remarkable advancements it has led to revolutionize medicine. Locus is dedicated to pushing #biotechnology boundaries, creating a new class of bacteriophage biotherapeutics using #PrecisionMedicine.

🎉 Thrilled to announce that the Locus team exceeded our fundraising goal of $20,000 for the @CrohnsColitisFn Triangle Take Steps Walk!🚶‍♂️💙 We proudly walked in solidarity to raise #IBDAwareness. Huge thanks to all supporters!

#ICYMI last week, Locus received $23.9M in funding from @BARDA to advance LBP-EC01, our first-in-class #CRISPR-engineered #bacteriophage therapy, into Part 2 of our Phase 2 ELIMINATE trial for treating #UTIs caused by drug-resistant E. coli. Read more➡️locus-bio.com/locus-bioscien…

We’re thrilled to announce we've received funding from @BARDA to advance LBP-EC01, our first-in-class #CRISPR-engineered #bacteriophage therapy, into Part 2 of our Phase 2 ELIMINATE trial for treating #UTIs caused by drug-resistant E. coli. Read more ➡️globenewswire.com/news-relea…